Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

The experimental treatment, TERN-601, is part of the second generation of weight-loss drugs, which aim to offer a more ...

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also ...

A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.

In this article, we take a look at six biotech companies focused on bringing drugs to treat obesity to the market.

Pfizer is pushing ahead with trials for a once-a-day weight loss pill as drug makers race to develop obesity treatments that are easier to take. The US pharmaceutical company said it was planning ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory ...

According to results from a phase 1 study released in July, patients taking the CT-996 pill experienced mean weight loss of 7.3% ... positions in and recommends Pfizer. The Motley Fool recommends ...